|
Ixico - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Says the discontinuation of two Huntington’s disease programmes by existing clients reduces its contracted order book by around £1.5 million over the next two financial years. Ixico notes it secured £8.0 million of new Huntington’s disease programme awards in the first half and says its order book remains 21% above the end of financial 2025. It adds that programme cancellations are a normal feature of drug development and reiterates recently upgraded guidance for financial 2026 and its outlook for 2027. ‘HD remains one of the most active and well-funded areas of neuroscience drug development, alongside Alzheimer’s and Parkinson’s disease. Investment continues across both established and emerging therapeutic approaches, supporting an increasingly diversified pipeline of clinical programmes for Ixico and hope for patients,’ the firm says. Current stock price: 8.10 pence, down 12% on Monday morning in London 12-month change: down 17% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
